Is gabapentin or ropinirole better for Restless Legs?
For most people starting a medicine today, gabapentin-type drugs are the better first choice for Restless Legs, and ropinirole is no longer the default. The 2024 AASM guideline (Winkelman et al., 2024) makes that call on one ground: augmentation, where ropinirole and pramipexole gradually make the legs start earlier and feel worse.
That will feel upside down if you have been on ropinirole for years. You did nothing wrong. Until 2024, ropinirole and pramipexole (sold in Australia as Sifrol) were the standard starting point, and they do work well at first. What changed is that the long-term evidence caught up with what patients had been reporting in waiting rooms.
The catch is that “better” is not the same as “harmless”. Gabapentin, pregabalin and gabapentin enacarbil have their own side effects, mostly drowsiness, dizziness and weight gain. So the honest comparison is not good drug versus bad drug. It is a medicine that tends to wear out badly against a medicine that tends to wear you out a little.
Gabapentin vs ropinirole: the side-by-side comparison
Seeing the two drugs side by side takes most of the confusion out of the GP conversation. The table sets out what the 2024 guideline says about each and the trade-offs you are actually choosing between. The drug-free column is there because the guideline counts iron correction and non-drug approaches as part of the plan, not an afterthought.
| Gabapentin, pregabalin, gabapentin enacarbil | Ropinirole, pramipexole (Sifrol) | Targeted overnight compression | |
|---|---|---|---|
| Drug class | Alpha-2-delta ligands (gabapentinoids) | Dopamine agonists | Not a drug |
| 2024 AASM guideline position | Strong recommendation for use when a medicine is wanted | Conditional recommendation against routine ongoing use | Not rated by the guideline; evidence from separate trials |
| Main long-term risk | Drowsiness, dizziness, weight gain, mood changes in some people | Augmentation: symptoms start earlier and spread over time | None reported in the published trials |
| How fast it works | Days to a couple of weeks as the dose settles | Often within days | Same night for some, over weeks for others |
| Wearing off over years | Not the augmentation pattern | The augmentation pattern is the known problem | Not applicable |
| Who it suits | Someone who wants a tablet and has no history of falls or heavy sedation | Short-term or intermittent use under close review, per the guideline | Anyone wanting a drug-free layer, on its own or beside a medicine |
The row that matters most is the long-term one. Both drug classes can settle your legs this month. Only one has a documented pattern of turning on you a few years in, and that pattern is why the guideline moved.
Why did the 2024 guideline move away from ropinirole?
The guideline moved because a meaningful share of long-term ropinirole and pramipexole users got worse, not better, and the drug itself was the cause. Winkelman et al. (2024) issued a conditional recommendation against routine ongoing use of the dopamine agonists on augmentation grounds. If your evening symptoms have crept into the afternoon, that is the pattern they mean.
Augmentation is disorienting because it looks like the disease progressing when it is the treatment doing it. Augmentation, and how to recognise it, is its own story. The short version: earlier onset, spread to the arms or trunk, and a shorter window of relief after each dose. Raising the dose helps for a while, then makes it worse.
There is a second, more hopeful reason the guideline reads the way it does. It strongly recommends checking and correcting iron first, including intravenous ferric carboxymaltose for adults with ferritin under 100 micrograms per litre (Winkelman et al., 2024). It also names triggers to deal with before any tablet: sedating antihistamines, some antidepressants, alcohol, caffeine and untreated sleep apnoea.
Whichever drug is on the table, your ferritin level is the first thing to ask about. Correcting low iron sometimes reduces how much medicine you need at all.
What does the research say about gabapentin for Restless Legs?
Wanting proof that holds for a year is fair, and the strongest trial offers it. Allen et al. (2014), in the New England Journal of Medicine, randomised 719 adults to pregabalin 300 mg, pramipexole 0.25 or 0.5 mg, or placebo. At 52 weeks, 72.2 per cent on pregabalin were rated improved, against 57.1 and 68.2 per cent on pramipexole.
The number that changed practice was augmentation, not improvement. In the same trial, augmentation was significantly lower with pregabalin than with pramipexole 0.5 mg over the year (Allen et al., 2014). Two things keep that honest: the trial was manufacturer-sponsored, and pregabalin brought more dizziness, drowsiness, weight gain and suicidal ideation than pramipexole.
If you were hoping for a big trial of gabapentin against ropinirole, the evidence is thinner. Happe et al. (2003), in Neuropsychobiology, gave 16 adults either drug for four weeks in an open trial and found both helped. Sixteen people over a month is a starting point, not a verdict. The guideline leans on the whole body of gabapentinoid trials.
How do you switch from ropinirole to gabapentin safely?
Switching is a GP or specialist decision, and the good news is that it is a well-trodden path. Nobody should stop ropinirole cold because of an article, this one included. Stopping a dopamine agonist suddenly usually brings a sharp rebound for a few nights, and that rebound is what pushes people straight back onto the drug.
What the switch usually looks like, based on the 2024 guideline’s priorities:
- Check ferritin and transferrin saturation first. Low iron may be doing more of the damage than the drug.
- Start the gabapentinoid low, in the evening, and build it up over one to two weeks while the ropinirole is still on board.
- Taper the ropinirole slowly rather than stopping it, expecting a rough week or two in the middle.
- Deal with the triggers the guideline names: sedating antihistamines, alcohol near bed, late caffeine, and get snoring assessed.
- Add a drug-free layer so the new medicine is doing less of the heavy lifting from the start.
That fourth step trips up more people than the tapering does. Have you tried tonic water? Yeah, most people on ropinirole have tried that too, along with the bar of soap under the sheet. The triggers on that list are less exciting and far better supported.
If you are on Sifrol rather than ropinirole, the same logic applies. Our guide to Sifrol and Restless Legs covers dose, side effects and the exit plan, and the pramipexole alternatives piece walks through each option.
Where does drug-free compression fit beside either drug?
Compression fits beside either tablet, not instead of your GP, carrying some of the load so the medicine can stay low. The controlled evidence is Lettieri and Eliasson (2009), in Chest: a randomised, double-blinded, sham-controlled trial of pneumatic compression in 35 adults. Severity fell roughly 40 per cent against sham, and about a third reported complete relief.
Wanting to keep the dose as low as possible is the right instinct, because both drug classes get harder to live with as the dose rises. A drug-free layer has no augmentation pattern to worry about and nothing to taper later. It is the one column in the table with nothing in the long-term-risk row.
Targeted foot compression, worn overnight, is the approach Stillr is built around. Kuhn et al. (2016) followed 30 adults using it over eight weeks and recorded a 90 per cent improvement on the Clinical Global Impression scale, against the 63 per cent published for ropinirole. The study had no control group, so the ropinirole figure came from earlier separate trials.
For the full picture of the drug-free options with evidence behind them, see our complete guide to drug-free Restless Legs treatment.
What the research actually shows
The relief you are after is a plan you can trust for years, not weeks, and that is what the research below was built to test.
The guideline. Winkelman et al. (2024), American Academy of Sleep Medicine Clinical Practice Guideline, Journal of Clinical Sleep Medicine. Conditional recommendation against routine ongoing use of ropinirole and pramipexole, on augmentation grounds. Strong recommendation for gabapentin enacarbil, gabapentin and pregabalin where medication is warranted, and for intravenous iron when ferritin is under 100 micrograms per litre. It does not say drug therapy is no longer recommended.
The year-long comparison. Allen et al. (2014), New England Journal of Medicine. 719 adults, 52 weeks, pregabalin 300 mg versus pramipexole 0.25 or 0.5 mg versus placebo. Improvement in 72.2, 57.1 and 68.2 per cent respectively. Augmentation significantly lower with pregabalin than with pramipexole 0.5 mg. Manufacturer-sponsored; pregabalin carried more dizziness, drowsiness, weight gain and suicidal ideation.
The direct but small comparison. Happe et al. (2003), Neuropsychobiology. 16 adults, four weeks, open trial, gabapentin versus ropinirole. Both relieved symptoms. Too small to rank the two drugs against each other.
The controlled compression evidence. Lettieri and Eliasson (2009), Chest. 35 adults, randomised, double-blinded, sham-controlled. About a 40 per cent fall in symptom severity, about one third with complete relief, none on sham.
The targeted foot compression evidence. Kuhn et al. (2016), Journal of the American Osteopathic Association. 30 adults, eight weeks, single-arm and open-label. 90 per cent rated much or very much improved. No control group: the 63 per cent ropinirole figure came from the authors’ meta-analysis of earlier, separate ropinirole trials.
What Stillr is, and isn’t
Stillr is a drug-free compression sleeve worn overnight to calm Restless Legs, designed in Australia. It is not a medicine, not a medical device, and not a replacement for the conversation above with your GP. It has no electronics and no batteries, sits on both feet, and is built to be worn all night. Stillr is pre-launch: a flat AUD $169 per pair, two sizes, a 60-Night Sleep Trial with return postage covered. Reserve a pair at stillr.com.au.
Drug-free, on your own terms, beside whatever your GP recommends: if that is the plan you want, join the founders’ list and we will let you know when your pair is ready.